Precision BioSciences vs Intellia Therapeutics
DTIL and NTLA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DTIL and NTLA compare
Intellia Therapeutics is the larger company, worth 6.5 times as much as Precision BioSciences ($1.4B against $209M).
Precision BioSciences grew revenue faster over the last twelve months (6353% versus −8.1% for Intellia Therapeutics).
Precision BioSciences keeps more of each dollar of sales as profit, with a net margin of −85.6% compared with −806% at Intellia Therapeutics.
Precision BioSciences scores higher on the StockData Score (4 against 3 for Intellia Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DTIL | NTLA |
|---|---|---|
| Size and price | ||
| Market cap | $209M | $1.4B |
| Share price | $7.57 | $9.70 |
| Change, 1 year | 26.1% | 2.2% |
| Change, 5 years | −97.3% | −92.5% |
| Beta (5Y) | 1.27 | 2.08 |
| Employees | 68 | 377 |
| StockData Score | ||
| Total score | 4 (better) | 3 |
| Valuation score | 0 | 0 |
| Growth score | 2 (better) | 0 |
| Performance score | 1 | 1 |
| Health score | 1 | 2 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 4.6× (better) | 25.7× |
| P/B | 4.0× | 2.2× (better) |
| FCF yield | −24.8% (better) | −26.3% |
| Fair value | $4.52 | $7.77 |
| Margin of safety | −67.5% | −24.9% (better) |
| Growth | ||
| Revenue growth (TTM) | 6353% (better) | −8.1% |
| Revenue growth, 5Y average | 7.1% (better) | 3.1% |
| Profitability | ||
| Operating margin | −80.3% (better) | −821% |
| Net margin | −85.6% (better) | −806% |
| FCF margin | −115% (better) | −677% |
| Return on equity | −113% | −62.6% (better) |
| Return on invested capital | – | −152% |
| Financial health | ||
| Debt / equity | – | 0.12 |
| Interest coverage | −28.6× | – |
| Current ratio | 10.47 (better) | 6.31 |
| Altman Z-score | −4.84 | −2.68 (better) |
| Piotroski F-score | 2 | 3 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 64.0% | 103% |
| Held by insiders | 3.0% | 2.0% |
| Insider net buying, 12 months | −$396K (better) | −$869K |
| Short interest, % of float | 7.8% | 32.3% |
Go deeper
- DTIL stock overview
- DTIL income statement
- DTIL valuation and score
- NTLA stock overview
- NTLA income statement
- NTLA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.